Tower Research Capital (TRC)’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $37K | Buy |
3,971
+1,662
| +72% | +$15K | ﹤0.01% | 3004 |
|
|
2025
Q4 | $20.7K | Sell |
2,309
-816
| -26% | -$7.72K | ﹤0.01% | 3076 |
|
|
2025
Q3 | $29.7K | Sell |
3,125
-6,812
| -69% | -$68.3K | ﹤0.01% | 2936 |
|
|
2025
Q2 | $87.5K | Buy |
9,937
+8,552
| +617% | +$69.4K | ﹤0.01% | 2487 |
|
|
2025
Q1 | $10.4K | Sell |
1,385
-232
| -14% | -$1.84K | ﹤0.01% | 3643 |
|
|
2024
Q4 | $13.5K | Sell |
1,617
-5,618
| -78% | -$48K | ﹤0.01% | 3524 |
|
|
2024
Q3 | $50.2K | Sell |
7,235
-1,621
| -18% | -$11K | ﹤0.01% | 2720 |
|
|
2024
Q2 | $43.4K | Buy |
8,856
+8,585
| +3,168% | +$40.7K | ﹤0.01% | 3210 |
|
|
2024
Q1 | $1.57K | Sell |
271
-9,402
| -97% | -$57.8K | ﹤0.01% | 5242 |
|
|
2023
Q4 | $63.4K | Buy |
9,673
+5,545
| +134% | +$25.9K | ﹤0.01% | 2974 |
|
|
2023
Q3 | $19.9K | Buy |
4,128
+1,669
| +68% | +$8.33K | ﹤0.01% | 3378 |
|
|
2023
Q2 | $12.5K | Buy |
+2,459
| New | +$13.3K | ﹤0.01% | 3859 |
|
|
2023
Q1 | – | Sell |
-16,026
| Closed | -$74K | – | 6350 |
|
|
2022
Q4 | $74K | Buy |
16,026
+9,985
| +165% | +$50.7K | ﹤0.01% | 2066 |
|
|
2022
Q3 | $38K | Sell |
6,041
-233
| -4% | -$1.32K | ﹤0.01% | 3408 |
|
|
2022
Q2 | $28K | Sell |
6,274
-21,969
| -78% | -$100K | ﹤0.01% | 3459 |
|
|
2022
Q1 | $142K | Buy |
28,243
+10,896
| +63% | +$69.3K | ﹤0.01% | 1976 |
|
|
2021
Q4 | $151K | Buy |
17,347
+15,146
| +688% | +$135K | ﹤0.01% | 1972 |
|
|
2021
Q3 | $21K | Buy |
2,201
+295
| +15% | +$2.97K | ﹤0.01% | 3682 |
|
|
2021
Q2 | $24K | Sell |
1,906
-63,079
| -97% | -$678K | ﹤0.01% | 3740 |
|
|
2021
Q1 | $597K | Buy |
+64,985
| New | +$567K | 0.01% | 1089 |
|
|
2019
Q1 | – | Sell |
-332
| Closed | -$9K | – | 4349 |
|
|
2018
Q4 | $9K | Buy |
332
+126
| +61% | +$5.1K | ﹤0.01% | 2580 |
|
|
2018
Q3 | $16K | Sell |
206
-203
| -50% | -$15.9K | ﹤0.01% | 2494 |
|
|
2018
Q2 | $43K | Buy |
409
+404
| +8,080% | +$39.4K | ﹤0.01% | 1931 |
|
|
2018
Q1 | $1K | Buy |
+5
| New | +$483 | ﹤0.01% | 3114 |
|
|
2017
Q4 | – | Sell |
-153
| Closed | -$9K | – | 4094 |
|
|
2017
Q3 | $9K | Sell |
153
-28
| -15% | -$1.49K | ﹤0.01% | 3123 |
|
|
2017
Q2 | $12K | Buy |
181
+165
| +1,031% | +$10.9K | ﹤0.01% | 1528 |
|
|
2017
Q1 | $1K | Sell |
16
-40
| -71% | -$2.43K | ﹤0.01% | 2868 |
|
|
2016
Q4 | $3K | Sell |
56
-154
| -73% | -$9.45K | ﹤0.01% | 3300 |
|
|
2016
Q3 | $15K | Buy |
+210
| New | +$14.9K | ﹤0.01% | 1805 |
|
|
2016
Q2 | – | Sell |
-43
| Closed | -$10K | – | 5063 |
|
|
2016
Q1 | $10K | Buy |
43
+38
| +760% | +$9.2K | ﹤0.01% | 1990 |
|
|
2015
Q4 | $2K | Sell |
5
-1
| -17% | -$271 | ﹤0.01% | 3832 |
|
|
2015
Q3 | $2K | Buy |
+6
| New | +$1.84K | ﹤0.01% | 3418 |
|
Other funds holding ZVRA
WP
NCM
VCM
ACM
Tower Research Capital (TRC)'s ZVRA Position: Q1 2026 in Review
Tower Research Capital (TRC) increased its Zevra Therapeutics (ZVRA) stake by 72% in Q1 2026, buying an estimated $15K and bringing the position to 3,971 shares worth $37K. The position accounts for ﹤0.01% of the portfolio, ranked #3004.
Tower Research Capital (TRC) first reported a position in ZVRA in Q3 2015 and has held it in 32 quarters since. The position peaked at $597K in Q1 2021. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.
- Tower Research Capital (TRC) held 3,971 shares of Zevra Therapeutics worth $37K as of Q1 2026.
- Tower Research Capital (TRC) bought 1,662 Zevra Therapeutics shares in Q1 2026, an estimated $15K.
- Zevra Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3004 holding.
- Tower Research Capital (TRC) first reported a position in Zevra Therapeutics in Q3 2015 and has held it in 32 quarters since.
- Tower Research Capital (TRC)'s Zevra Therapeutics position peaked at $597K in Q1 2021.
- 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.